Alzamend Neuro (NASDAQ:ALZN) Trading 0.9% Higher – What’s Next?

Alzamend Neuro, Inc. (NASDAQ:ALZN) was up 0.9% during mid-day trading on Wednesday . The company traded as high as $1.16 and last traded at $1.16. Approximately 41,641 shares were traded during mid-day trading, a decline of 31% from the average daily volume of 59,984 shares. The stock had previously closed at $1.15.

Analyst Ratings Changes

Separately, Weiss Ratings raised shares of Alzamend Neuro from a “sell (e)” rating to a “sell (e+)” rating in a research report on Thursday, May 21st. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $28.00.

Alzamend Neuro Stock Up 0.9%

The stock has a market cap of $4.41 million, a P/E ratio of -0.54 and a beta of 0.16. The firm’s 50-day moving average is $1.07 and its two-hundred day moving average is $1.70.

Alzamend Neuro (NASDAQ:ALZN) last issued its quarterly earnings data on Wednesday, March 11th. The company reported ($0.58) earnings per share for the quarter, missing the consensus estimate of ($0.53) by ($0.05). Analysts anticipate that Alzamend Neuro, Inc. will post -2.58 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Alzamend Neuro news, Director Milton C. Ault III acquired 108,388 shares of the business’s stock in a transaction that occurred on Tuesday, April 14th. The shares were purchased at an average price of $1.00 per share, with a total value of $108,388.00. Following the completion of the transaction, the director owned 116,648 shares in the company, valued at $116,648. The trade was a 1,312.20% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 1.39% of the company’s stock.

Hedge Funds Weigh In On Alzamend Neuro

An institutional investor recently raised its position in Alzamend Neuro stock. DRW Securities LLC boosted its holdings in shares of Alzamend Neuro, Inc. (NASDAQ:ALZN) by 27.5% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 116,319 shares of the company’s stock after acquiring an additional 25,074 shares during the quarter. DRW Securities LLC owned approximately 3.06% of Alzamend Neuro worth $212,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 49.61% of the company’s stock.

Alzamend Neuro Company Profile

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.